Table 4.

Effect Size Estimates Comparing the Sensitivity and Main Analysis Results

Exposure Definition	Risk ratio (95% CI) Main Analysis	Risk ratio (95% CI) Sensitivity Analysis
⩾1 Tdap or Td without TT	0.7059 (0.6876–0.7247)	0.6783 (0.6427–0.7161)
⩾1 Zostavax or Shingrix	0.7520 (0.7378–0.7666)	0.7122 (0.6860–0.7395)
⩾1 PCV-13 or PPSV-23	0.7304 (0.7186–0.7424)	0.7316 (0.7069–0.7572)

For both groups of analyses, we compared two cohorts (vaccinated and unvaccinated) constructed using propensity score matching (PSM). For the main analysis (the same analysis presented in Table 3), the look back period was defined as 2009–2011 and the follow up period as 2011–2019. The sensitivity analysis look back period was split into two halves: 2009–2010 for identification of patients who filled at least one statin prescription, and 2010–2011 for determining which of those patients had at least 80% proportion of days covered by statin therapy. The follow up period spanned from 2011–2019. CI, Confidence Interval; PCV-13, pneumococcal conjugate vaccine 13; PPSV-23, Pneumococcal polysaccharide vaccine 23; Tdap, Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; Td, Tetanus toxoid and reduced diphtheria toxoid; TT, Tetanus toxoid.